Atorvastatin

Chemical formula: C₃₃H₃₅FN₂O₅ Molecular mass: 558.64 g/mol PubChem compound: 60823

Therapeutic indications

Atorvastatin is indicated for:

Cardiovascular event

Population group: only adults (18 years old or older)

Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

To reduce the risk of:

Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD.
MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD.
Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg once daily for at least 4 weeks and thefeafter 10-80 mg once daily

Primary hypercholesterolaemia, combined hyperlipidaemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of

Primary hypercholesterolemia
Mixed hyperlipidaemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg once daily

Heterozygous familial hypercholesterolaemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Familial hypercholesterolaemia - heterozygous

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg once daily for 4 weeks and thereafter 10-80 mg once daily

10 mg once daily for 4 weeks and thereafter 10-20 mg once daily

Homozygous familial hypercholesterolaemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Familial hypercholesterolemia - homozygous

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg once daily for at least 4 weeks and thereafter 80 mg once daily

Primary hyperlipidemia

Population group: only adults (18 years old or older)

As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10-20 mg once daily for at least 4 weeks and thereafter 10-80 mg once daily

Primary dysbetalipoproteinemia

Population group: only adults (18 years old or older)

Familial type 3 hyperlipoproteinaemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10-20 mg once daily for 4 weeks and thereafter 10-80 mg once daily

Hypertriglyceridemia

Population group: only adults (18 years old or older)

Hypertriglyceridaemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10-20 mg once daily for 4 weeks and thereafter 10-80 mg once daily

Contraindications

Atorvastatin is contraindicated in the following cases:

Glecaprevir/pibrentasvir

at least one of

Glecaprevir and pibrentasvir
Glecaprevir
Pibrentasvir

Pregnancy

Pregnancy

Lactation

Lactation

Active liver disease, unexplained persistent elevations of serum transaminases

at least one of

Hepatopathy
Elevated liver enzymes level

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈